Eaton-Cambridge’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.11M Buy
927
+53
+6% +$54.2K 0.31% 22
2026
Q1
$804K Buy
874
+148
+20% +$150K 0.25% 24
2025
Q4
$780K Buy
726
+29
+4% +$27.7K 0.26% 20
2025
Q3
$532K Hold
697
0.19% 27
2025
Q2
$543K Buy
697
+5
+0.7% +$3.88K 0.21% 24
2025
Q1
$572K Hold
692
0.25% 22
2024
Q4
$534K Hold
692
0.24% 19
2024
Q3
$613K Sell
692
-13
-2% -$11.7K 0.29% 17
2024
Q2
$638K Buy
705
+9
+1% +$7.2K 0.33% 16
2024
Q1
$541K Sell
696
-3
-0.4% -$2.13K 0.29% 17
2023
Q4
$407K Buy
+699
New +$408K 0.25% 21

Other funds holding LLY

Eaton-Cambridge's LLY Position: Q2 2026 in Review

Eaton-Cambridge increased its Eli Lilly (LLY) stake by 6.1% in Q2 2026, buying an estimated $54.2K and bringing the position to 927 shares worth $1.11M. The position accounts for 0.31% of the portfolio, ranked #22.

Eaton-Cambridge first reported a position in LLY in Q4 2023 and has held it in 11 quarters since. 1,842 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Eaton-Cambridge held 927 shares of Eli Lilly worth $1.11M as of Q2 2026.
  • Eaton-Cambridge bought 53 Eli Lilly shares in Q2 2026, an estimated $54.2K.
  • Eli Lilly made up 0.31% of Eaton-Cambridge's portfolio in Q2 2026, its #22 holding.
  • Eaton-Cambridge first reported a position in Eli Lilly in Q4 2023 and has held it in 11 quarters since.
  • 1,842 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Eaton-Cambridge's 13F filing for Q2 2026, filed 23 Jul 2026.